塞拉德尔帕治疗降低了原发性胆道胆炎患者的IL-31和
Andreas E Kremer1, Marlyn J Mayo2, Gideon M Hirschfield3
1Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Hepatology (Baltimore, Md.)
|December 20, 2023
概括
塞拉德尔帕在初级胆道胆炎 (PBC) 患者中显著降低了和血清IL-31水平. 这些减少与胆汁酸的减少相关,这表明seladelpar的机制.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 是原发性胆道胆炎 (PBC) 的重要症状.
- 塞拉德尔帕是一种PPAR-delta激动剂,在改善PBC患者的和减少胆酸方面表现出有效性.
- 介乐-31 (IL-31) 是一种关键的细胞因子,与中介性有关.
研究的目的:
- 研究seladelpar的抗效应与PBC患者IL-31和胆酸水平之间的关系.
- 探索seladelpar在缓解的有效性的潜在机制.
主要方法:
- 在ENHANCE研究中的PBC患者中测量了血清IL-31水平,这些患者接受了安慰剂或塞拉德帕 (5mg或10mg) 治疗3个月.
- IL-31水平与的严重程度 (NRS) 和血清胆酸水平相关.
- 分析了IL-31和胆酸的变化与改善的关系.
主要成果:
- 基线IL-31水平与的严重程度和胆酸度有很强的相关性.
- 与安慰剂相比,塞拉德尔帕治疗导致血清IL-31水平的剂量依赖性显著降低.
- 经历有意义的缓解的患者显示IL-31的减少更大,这与胆汁酸的减少相关.
结论:
- 在PBC患者中,塞拉德尔帕有效降低血清IL-31和胆酸水平.
- 观察到的IL-31和胆酸的减少与的改善相关.
- 这表明IL-31调节,胆酸降低和seladelpar. antipruritic作用之间的机制联系.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
179
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
179
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
01:29Chronic Pancreatitis II: Collaborative Care
92
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
92
01:17Chronic Bowel Disorders: Introduction
456
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
456
01:21Drugs for Treatment of Constipation-Predominant IBS
176
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
176
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168